Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant747 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,431 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00001426 | A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer | completed | Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2018 | clinicaltrials |
| NCT01653912 | Dose-finding Study in Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 59 | AccentureINDUSTRY | 3 | Apr 2, 2018 | clinicaltrials |
| NCT00880360 | A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer(ONTAK) | completed | Phase 2 | 19 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Mar 27, 2018 | clinicaltrials |
| NCT00443196 | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas | completed | Phase 2 / Phase 3 | 150 | Pierian BiosciencesINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01188876 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00499252 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01118052 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00381888 | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | completed | Phase 2 | 44 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00610740 | CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer | completed | Phase 2 | 18 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00617188 | Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer | completed | Phase 2 | 26 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01105650 | Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer | completed | Phase 2 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00908960 | Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles(MicroTEC) | completed | Phase 2 | 70 | Beth Israel Deaconess Medical CenterOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT01617629 | Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study(CAN-003X) | completed | Phase 2 | 9 | Prima BioMed LtdINDUSTRY | 2 | Dec 8, 2017 | clinicaltrials |
| NCT02454036 | Biobehavioral Intervention in Gynecologic Oncology Patients | completed | Phase 2 | 6 | Rachel MillerOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00334893 | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00470366 | Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors | completed | Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00937560 | A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 9 | Nov 6, 2017 | clinicaltrials |
| NCT00857545 | OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission | completed | Phase 2 | 171 | Gynecologic Oncology GroupNETWORK | 1 | Sep 13, 2017 | clinicaltrials |
| NCT01039207 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Sep 7, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00408603 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer | completed | Phase 2 | 183 | Sunesis PharmaceuticalsINDUSTRY | 2 | Jul 27, 2017 | clinicaltrials |
| NCT00856791 | Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | completed | Phase 2 | 1 | Traws Pharma, Inc.INDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01905163 | Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients(CILOVE) | completed | Phase 2 | 47 | Centre Jean PerrinOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00045682 | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 78 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00054119 | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00511992 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | completed | Phase 2 | 20 | University of OklahomaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00061308 | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer | completed | Phase 2 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Jun 9, 2017 | clinicaltrials |
| NCT00739661 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission | completed | Phase 2 | 104 | Genentech, Inc.INDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT01462149 | Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer | completed | Phase 2 | 43 | Asan Medical CenterOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT01175343 | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT00097019 | A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed | completed | Phase 2 | 53 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT00780039 | A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) | completed | Phase 2 | 58 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 15, 2017 | clinicaltrials |
| NCT01068509 | Ovarian Cancer Vaccine for Patients in Remission | completed | Phase 2 | 63 | Prima BioMed LtdINDUSTRY | 2 | May 11, 2017 | clinicaltrials |
| NCT01276548 | A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer(GPMOC202) | completed | Phase 2 | 102 | Samyang Biopharmaceuticals CorporationINDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT00157573 | GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer | completed | Phase 2 | 72 | Massachusetts General HospitalOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT01306032 | Phase II ABT-888 With Cyclophosphamide | completed | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 2 | Apr 26, 2017 | clinicaltrials |
| NCT00545792 | Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00957905 | Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00321932 | Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | University of MinnesotaOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00058552 | A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer | completed | Phase 2 | 129 | Genentech, Inc.INDUSTRY | 0 | Mar 8, 2017 | clinicaltrials |
| NCT00523380 | Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer | completed | Phase 2 | 10 | Novo Nordisk A/SINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT00002931 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer | completed | Phase 2 | 48 | City of Hope Medical CenterOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00158379 | Taxol Carboplatin and Erythropoetin | completed | Phase 2 | 105 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Feb 6, 2017 | clinicaltrials |
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00073541 | A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer | completed | Phase 2 | 38 | EMD SeronoINDUSTRY | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00872989 | S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 129 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 19, 2016 | clinicaltrials |
| NCT00314678 | Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer | completed | Phase 2 | 40 | John P. FruehaufOTHER | 1 | Dec 8, 2016 | clinicaltrials |
| NCT00179712 | Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | completed | Phase 1 / Phase 2 | 60 | Celgene CorporationINDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Apr 5, 2018source: clinicaltrials